Precipio Continues to Sign New HemeScreen™ Customers
New customer orders received in Q3 exceed $1M annualized revenue NEW HAVEN, CT, Globenewswire – [...]
Sep
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
Higher pathology revenues and lower cost structure drive down product revenue breakeven point from $8M [...]
Sep
Precipio Takes Final Step Towards Regaining Nasdaq Compliance
Company announces 1-for-20 reverse stock split NEW HAVEN, CT – (September 21, 2023) – Specialty [...]
Sep
Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
Company continues to make strides towards profitability NEW HAVEN, CT, Globenewswire – (September 13, 2023) – [...]
Sep
Precipio Announces Q2-2023 Shareholder Update Call
Conference Call to be held on August 17, 2023 at 5:00 PM EST NEW HAVEN, [...]
Aug
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
Advanced panel already generating six-figure pre-orders NEW HAVEN, CT, Globenewswire – (August 8, 2023) – Specialty [...]
Aug
Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
Revenue growth and customer pipeline advance the Company towards breakeven NEW HAVEN, CT, Globenewswire – [...]
Aug
Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023
Revenue growth and customer pipeline advance the Company towards breakeven NEW HAVEN, CT, Globenewswire – [...]
Aug
Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology
New panel will enable rapid, precise genetic profiling of patients with deadly disease NEW HAVEN, [...]
Jun
Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
NEW HAVEN, CT, (June 8th, 2023) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it [...]
Jun